- Home
- AZTR vs SXTP Comparison
AZTR vs SXTP Comparison
Compare AZTR & SXTP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AZTR
- SXTP
- Stock Information
- Founded
- AZTR 2014
- SXTP 2010
- Country
- AZTR United States
- SXTP United States
- Employees
- AZTR N/A
- SXTP N/A
- Industry
- AZTR Biotechnology: Pharmaceutical Preparations
- SXTP Biotechnology: Pharmaceutical Preparations
- Sector
- AZTR Health Care
- SXTP Health Care
- Exchange
- AZTR Nasdaq
- SXTP Nasdaq
- Market Cap
- AZTR 3.7M
- SXTP 3.4M
- IPO Year
- AZTR 2023
- SXTP 2023
- Fundamental
- Price
- AZTR $0.80
- SXTP $1.39
- Analyst Decision
- AZTR
- SXTP Buy
- Analyst Count
- AZTR 0
- SXTP 2
- Target Price
- AZTR N/A
- SXTP $3.00
- AVG Volume (30 Days)
- AZTR 7.5M
- SXTP 88.9K
- Earning Date
- AZTR 08-11-2025
- SXTP 08-13-2025
- Dividend Yield
- AZTR N/A
- SXTP N/A
- EPS Growth
- AZTR N/A
- SXTP N/A
- EPS
- AZTR N/A
- SXTP N/A
- Revenue
- AZTR N/A
- SXTP $984,494.00
- Revenue This Year
- AZTR N/A
- SXTP $81.41
- Revenue Next Year
- AZTR N/A
- SXTP $95.63
- P/E Ratio
- AZTR N/A
- SXTP N/A
- Revenue Growth
- AZTR N/A
- SXTP 128.70
- 52 Week Low
- AZTR $0.70
- SXTP $1.22
- 52 Week High
- AZTR $4.45
- SXTP $12.45
- Technical
- Relative Strength Index (RSI)
- AZTR 36.74
- SXTP 47.66
- Support Level
- AZTR $0.90
- SXTP $1.22
- Resistance Level
- AZTR $1.09
- SXTP $1.52
- Average True Range (ATR)
- AZTR 0.15
- SXTP 0.08
- MACD
- AZTR 0.01
- SXTP 0.04
- Stochastic Oscillator
- AZTR 15.32
- SXTP 57.38
About AZTR Azitra Inc
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.
About SXTP 60 Degrees Pharmaceuticals Inc.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.